Selected primary endpoints2
Safety and tolerability through Week 24
Selected secondary endpoints2
Efficacy, safety, and tolerability of an FTC/TAF-based regimen through Week 48
|Mean age, years||14|
|Mean plasma HIV-1 RNA, log10 copies/mL||4.8|
|HIV-1 RNA >100,000 copies/mL (%)||35|
|Median CD4+ cell count, cells/µL||456|
|CD4+ cell count <200 cells/µL (%)||13|
BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
DESCOVY® is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients 12 years and older.
Limitations of Use:
DESCOVY is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1 infection.
*Administered in combination with EVG and COBI as an STR.
QD, once daily.
By following this link, you are leaving www.descovy.com/hcp. This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site's content or your use of the site.
By following this link, you are leaving www.descovy.com/hcp